Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
Rhea-AI Summary
Protara Therapeutics (Nasdaq:TARA), a clinical-stage biotech developing therapies for cancer and rare diseases, will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on May 26, 2026 at 9:30 a.m. ET. The live webcast and a limited-time archive will be available in the Events and Presentations section of Protara’s investor relations website.
Positive
- None.
Negative
- None.
Details
News Market Reaction – TARA
In the May 20 session, TARA gained 9.68%, reflecting a notable positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
- Summit date
- May 26, 2026
- TD Cowen 7th Annual Oncology Innovation Summit participation
- Presentation time
- 9:30 am ET
- Scheduled virtual fireside chat at TD Cowen summit
- Summit edition
- 7th Annual
- TD Cowen Oncology Innovation Summit iteration
Historical Context
-
Announced investor webinar focused on TARA-002 in lymphatic malformations.
-
Reported durable 12-month complete responses in Phase 2 ADVANCED-2 BCG-naïve cohort.
-
Q1 2026 results with $177.4M cash and clear TARA-002 development timelines.
-
Planned presentation of updated interim 12‑month ADVANCED-2 data at AUA meeting.
-
FY 2025 update with promising ADVANCED‑2 data and cash of about $197.9M.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company committed to advancing transformative therapies for the treatment of cancer and rare diseases, today announced that management will participate in a virtual fireside chat at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA on Tuesday, May 26, 2026, at 9:30 am ET.
A live webcast of the presentation can be accessed by visiting the Events and Presentations section of the Company’s website: https://ir.protaratx.com. The webcast will be archived for a limited time following the presentation.
About Protara Therapeutics, Inc.
Protara is a clinical-stage biotechnology company committed to advancing transformative therapies for people with cancer and rare diseases. Protara’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is evaluating TARA-002 in an ongoing Phase 2 trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naïve to treatment with Bacillus Calmette-Guérin, as well as a Phase 2 trial in pediatric patients with LMs. Additionally, Protara is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral support who are otherwise unable to meet their choline needs via oral or enteral routes. For more information, visit www.protaratx.com.
Company Contact:
Justine O'Malley
Protara Therapeutics
Justine.OMalley@protaratx.com
646-817-2836
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.